Published in BMJ Open Respir Res on January 03, 2014
Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J (2015) 1.65
The future of the development of medicines in idiopathic pulmonary fibrosis. BMC Med (2015) 0.82
Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry. Lung India (2016) 0.75
Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res (2016) 0.75
Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med (2016) 0.75
Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res (2017) 0.75
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes (2006) 26.32
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
Quality of health care. Part 2: measuring quality of care. N Engl J Med (1996) 6.46
Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2006) 5.86
The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med (1994) 4.66
Bias. J Epidemiol Community Health (2004) 3.85
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax (2006) 2.59
Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest (1998) 2.57
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J (2010) 2.17
Minimally clinically important difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale. COPD (2005) 2.14
A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ (2003) 2.10
Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PLoS One (2007) 1.88
The role of cardiac registries in evidence-based medicine. Eur Heart J (2010) 1.83
What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ (1990) 1.61
Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. Am J Respir Crit Care Med (1994) 1.57
Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry. Int J Cardiol (2012) 1.48
Challenges in pulmonary fibrosis: 8--The need for an international registry for idiopathic pulmonary fibrosis. Thorax (2008) 1.48
Minimal clinically important difference for the UCSD Shortness of Breath Questionnaire. J Cardiopulm Rehabil (2005) 1.47
[The version 2.0 of the SF-36 Health Survey: results of a population-representative study]. Soz Praventivmed (2005) 1.28
Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf (2005) 1.20
Epidemiology of interstitial lung diseases in Greece. Respir Med (2009) 1.18
Are data from clinical registries of any value? Eur Heart J (2000) 1.10
Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health (2005) 1.01
Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med (2003) 0.97
Idiopathic pulmonary fibrosis. A rational clinical approach. Chest (1987) 0.93
[Assessment of quality of life in health services research - conceptual, methodological and structural prerequisites]. Gesundheitswesen (2009) 0.93
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung (2010) 0.87
[Characteristics and management of idiopathic pulmonary fibrosis: INSIGHTS-IPF registry]. Dtsch Med Wochenschr (2012) 0.81
[GOLDnet - focus on rare lung diseases]. Dtsch Med Wochenschr (2011) 0.77
International registry for idiopathic pulmonary fibrosis. Thorax (2008) 0.77